• A troubled Valeant has struck a deal to sell Dendreon and its prostate cancer vaccine Provenge to China’s Sanpower Group for $820 million. Valeant plans to pay down debt with the deal. Adding to the haul, Valeant is also selling skincare brands CeraVe, AcneFree and AMBI. The pharma company still has a long way to go, though, as it stares down $30 billion in debt.
• Bayer is tying up with the University of Pittsburgh on a “master collaboration agreement” to advance research for heart, lung and blood disease indications. This partnership covers early-stage research, drug development and big data analysis including real-world evidence studies. Bayer is also backing an independent investigator-initiated clinical trial in sickle cell disease.
• Sweden’s NeuroVive Pharmaceutical AB struck a collaboration agreement with Karolinska Institutet in Stockholm, Sweden, regarding development of the company’s compound NV556 for mitochondrial myopathy.
Get Endpoints News in your inbox
Newsletters for those who discover, develop, and market drugs. Join 13,000+ biopharma pros who read Endpoints News every day. Free subscription.
Subscribe to Endpoints
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.